Atara reported net income of $38.0 million, or $3.53 basic earnings per share and $3.50 diluted earnings per share, for the first quarter 2025, as compared to a net loss of $31.8 million, or $5.65 ...

THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and ...

The securities described above are being offered by Atara pursuant to a shelf registration statement on Form S-3 (No. 333-275256), including a base prospectus, that was previously filed by Atara ...

THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

But Monday, Atara told its remaining employees that 30% of them would be following their former colleagues out of the door. The latest changes will leave just 23 people working at the biopharma ...

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) Provided by Business Wire May 5, 2025, 9:06:00 PM ...

THOUSAND OAKS, Calif., May 05, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 68.85% and 150.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Atara reported net losses of $12.7 million, or $1.19 per share, and $85.4 million, or $11.41 per share, for the fourth quarter and fiscal year 2024, respectively, as compared to $60.5 million, or ...

THOUSAND OAKS, Calif., March 07, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Biotech Atara, reeling from FDA hold on Ebvallo, lays off half of workforce By James Waldron Mar 4, 2025 8:07am Atara Biotherapeutics Cell & Gene Therapy layoffs allogeneic cell therapy ...